First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306
media
posted on 2025-01-16, 16:55 authored by AdisRapid Journals on behalf of:, Jianming Xu, Ken Kato, Richard Hubner, Sook Ryun Park, Takashi Kojima, Ryu Ishihara, Lucjan Wyrwicz, Eric Van Cutsem, Paula Jimenez-Fonseca, Hongqian Wu, Lei Wang, Sebastian Yan, Jingwen Shi, Alysha Kadva, Harry H. Yoon
The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days. In the meantime, a pre-typeset version of the article is attached. This is not the final publication and may be subject to some minor changes.
